Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease.

We have developed a coevolutionary method for the computational design of HIV-1 protease inhibitors selected for their ability to retain efficacy in the face of protease mutation. For HIV-1 protease, typical drug design techniques are shown to be ineffective for the design of resistance-evading inhibitors: An inhibitor that is a direct analogue of one of the natural substrates will be susceptible to resistance mutation, as will inhibitors designed to fill the active site of the wild-type or a mutant enzyme. Two design principles are demonstrated: (i) For enzymes with broad substrate specificity, such as HIV-1 protease, resistance-evading inhibitors are best designed against the immutable properties of the active site-the properties that must be conserved in any mutant protease to retain the ability to bind and cleave all of the native substrates. (ii) Robust resistance-evading inhibitors can be designed by optimizing activity simultaneously against a large set of mutant enzymes, incorporating as much of the mutational space as possible.

[1]  C. Chothia.  Structural invariants in protein folding , 1975, Nature.

[2]  D. Veber,et al.  HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. , 1988, Biochemical and biophysical research communications.

[3]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[4]  L. Loeb,et al.  Fidelity of HIV-1 reverse transcriptase. , 1988, Science.

[5]  A. Skalka.  Retroviral proteases: First glimpses at the anatomy of a processing machine , 1989, Cell.

[6]  C. Hutchison,et al.  Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.

[7]  A. Tomasselli,et al.  A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. , 1991, The Journal of biological chemistry.

[8]  A. Wlodawer,et al.  Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites. , 1992, Biochemistry.

[9]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[10]  P. Darke,et al.  HIV protease as an inhibitor target for the treatment of AIDS. , 1994, Advances in pharmacology.

[11]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[12]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[13]  J. Tang,et al.  A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV‐1 proteases , 1995, FEBS letters.

[14]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[15]  L. Babe,et al.  Defining the Level of Human Immunodeficiency Virus Type 1 ( HIV-1 ) Protease Activity Required for HIV-1 Particle Maturation and Infectivity , 1995 .

[16]  M J Sippl,et al.  Knowledge-based potentials for proteins. , 1995, Current opinion in structural biology.

[17]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[18]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[19]  D. Fairlie,et al.  Targeting HIV-1 protease: a test of drug-design methodologies. , 1995, Trends in pharmacological sciences.

[20]  I T Weber,et al.  Molecular mechanics calculations on HIV-1 protease with peptide substrates correlate with experimental data. , 1996, Protein engineering.

[21]  K. Chou,et al.  Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method , 1996, Proteins.

[22]  J. Erickson,et al.  Structural mechanisms of HIV drug resistance. , 1996, Annual review of pharmacology and toxicology.

[23]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[24]  H. B. Schock,et al.  Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials , 1996, The Journal of Biological Chemistry.

[25]  Richard K. Belew,et al.  New Methods for Competitive Coevolution , 1997, Evolutionary Computation.

[26]  B. Torbett,et al.  Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.